GlassScriptPhysician profile
Joyce Ann Davis
NPI 1730578436
$2,004.90
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,271 · 2022: $734.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $333.20 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $269.53 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $255.06 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $185.83 | 2021-2022 | |
| Abbvie INC. | $157.59 | 2021-2022 | |
| Lundbeck LLC | $154.14 | 2021-2022 | |
| Eisai INC. | $115.96 | 2021-2022 | |
| Adlon Therapeutics L.P. | $113.70 | 2021 | |
| Vanda Pharmaceuticals INC. | $109.81 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $76.21 | 2022 | |
| Jazz Pharmaceuticals INC. | $55.97 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.73 | 2021-2022 | |
| Neos Therapeutics, LP | $43.11 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $31.72 | 2021-2022 | |
| Bausch Health US, LLC | $30.69 | 2021-2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $17.65 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.